What is the role of Von Willebrand factor in chronic hepatitis B virus infection to hepatocellular carcinoma: a review article.
| Autor: | Xiang Q; Medical Research Center, Institute of Medicine, Jishou University, Jishou, China., Tao JS; Medical Research Center, Institute of Medicine, Jishou University, Jishou, China., Li JJ; Medical Research Center, Institute of Medicine, Jishou University, Jishou, China., Tian RB; Medical Research Center, Institute of Medicine, Jishou University, Jishou, China., Li XH; Institute of Pharmaceutical Sciences, Jishou University, 120 Ren min south road, Jishou 416000, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Therapeutic advances in chronic disease [Ther Adv Chronic Dis] 2022 Nov 15; Vol. 13, pp. 20406223221125683. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022). |
| DOI: | 10.1177/20406223221125683 |
| Abstrakt: | Von Willebrand factor (VWF) is a glycoprotein synthesized and secreted by vascular endothelial cells and megakaryocytes, found on plasma surface, endothelial cells, and α-granule of platelets. VWF can be interacted with collagen and platelet membrane glycoproteins GPIb and GPIb-IIa and play an important role in platelet adhesion and aggregation. Growing research evidence suggests that VWF also mediates the prevention or protesting of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients from several clinical studies. While the mechanism of VWF in HCC protection or protest is still unclear, further study is required. This article aims to rationalize the role of VWF in the development of HCC, and the functional domain of VWF in cancer as well as cross-talking with platelets and miRNAs. This article also looks forward to the future development and challenges of VWF research. Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s), 2022.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|